Pharming Group Appoints Kenneth Lynard as CFO
Pharming Group N.V. has made a significant leadership change with the appointment of Kenneth Lynard as its Chief Financial Officer (CFO). His start date is set for October 1, 2025. Lynard, with over two decades of global financial experience in the life sciences sector, is expected to bolster the financial operations of Pharming as the company progresses on its growth trajectory.
Bringing Valuable Expertise
Kenneth Lynard is a seasoned professional recognized for his strong record in financial and operational transformation within complex organizations. This strategic hire comes following Pharming's impressive financial results in the first half of 2025, a period that has underscored the company’s potential for growth.
CEO's Perspective
Fabrice Chouraqui, Pharming's CEO, expressed enthusiasm regarding Lynard's appointment, emphasizing the value of Kenneth's diverse experience in both established firms and dynamic startups. His background includes operational roles in the U.S. and EU, positioning him to contribute significantly as Pharming aims to build a leading global rare disease company.
Prior Experience
Before joining Pharming, Mr. Lynard served as the CFO for Schoeller Allibert and Zentiva, a European pharmaceutical company. His extensive experience also includes a tenure at Affidea and a notable role at Gilead Sciences, where he was pivotal in steering the company's transformation during its expansion into new therapeutic areas and markets. His strategic involvement in capital allocation and funding played a significant role in scaling Gilead's business after the Pharmasset acquisition.
A Focus on Optimization
During his career, Lynard has held leadership roles at Medtronic, Coloplast, and Superfos. His foundational experience as a former public accountant with Arthur Andersen has equipped him with a robust understanding of compliance and internal controls, which he aims to leverage for optimizing Pharming's operations.
Kenneth Lynard's Vision
Expressing his excitement about joining Pharming, Lynard said, "I'm thrilled to step into the role at a crucial point in the company’s journey. The momentum Pharming has achieved, alongside forthcoming commercial opportunities, indicates a strong platform for sustainable success. My commitment is to reinforce operational efficiency and support enduring value creation for patients with rare diseases."
About Pharming Group N.V.
Pharming Group N.V. is a biopharmaceutical entity dedicated to changing the lives of patients suffering from rare, severe, and life-threatening diseases. The company prides itself on developing and commercializing a range of innovative therapeutics, including both small molecules and biologics. With its headquarters located in Leiden, the Netherlands, Pharming operates globally, catering to patients across more than 30 markets in regions including North America, Europe, and Asia-Pacific.
How to Learn More
For additional information about Pharming and its mission, please visit their official website.
Frequently Asked Questions
1. Who is the newly appointed CFO of Pharming Group?
The new CFO of Pharming Group is Kenneth Lynard, who will be starting on October 1, 2025.
2. What is Kenneth Lynard's professional background?
Lynard has over 20 years of experience in finance leadership, particularly in the life sciences sector, including significant roles at Gilead Sciences and Schoeller Allibert.
3. Why is Kenneth Lynard's appointment significant for Pharming?
His experience is expected to enhance financial leadership at Pharming, particularly as the company continues its strategic growth and navigates the competitive landscape of rare disease therapeutics.
4. What is Pharming Group's mission?
Pharming aims to transform the lives of patients affected by rare and debilitating diseases through innovative treatments.
5. How can I find more information about Pharming Group?
You can learn more about Pharming by visiting their official website, where they provide insights into their products and corporate strategies.
